Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Invested Capital (2016 - 2025)

Coherus Oncology's Invested Capital history spans 13 years, with the latest figure at $61.0 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 151.55% year-over-year to $61.0 million; the TTM value through Dec 2025 reached $61.0 million, up 151.55%, while the annual FY2025 figure was $61.0 million, 151.55% up from the prior year.
  • Invested Capital for Q4 2025 was $61.0 million at Coherus Oncology, down from $87.8 million in the prior quarter.
  • Across five years, Invested Capital topped out at $256.2 million in Q2 2021 and bottomed at -$196.3 million in Q1 2023.
  • The 5-year median for Invested Capital is -$78.4 million (2024), against an average of -$25.2 million.
  • The largest annual shift saw Invested Capital tumbled 1662.84% in 2023 before it soared 259.97% in 2025.
  • A 5-year view of Invested Capital shows it stood at $97.7 million in 2021, then crashed by 240.62% to -$137.4 million in 2022, then plummeted by 38.36% to -$190.1 million in 2023, then surged by 37.74% to -$118.4 million in 2024, then soared by 151.55% to $61.0 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Invested Capital are $61.0 million (Q4 2025), $87.8 million (Q3 2025), and $119.8 million (Q2 2025).